Erdafitinib-associated Central Serous Chorioretinopathy: A Case Report

Authors

  • Sierra Blanchard Southern Arizona VA Health Care System
  • Suzzane Li Southern Arizona VA Health Care System
  • Danielle Weiler Southern Arizona VA Health Care System

Keywords:

Erdafitinib, central serous chorioretinopathy, urothelial carcinoma, fibroblast growth factor receptor (FGFR) inhibition

Abstract

Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor approved to treat patients with metastatic or advanced urothelial carcinoma and is being developed for the treatment of other cancer types. This oral chemotherapeutic agent carries a warning for potential ocular adverse reactions including central serous chorioretinopathy and dry eyes. This case report describes an 88-year-old Caucasian male co-managed in the eye clinic over the course of treatment with erdafitinib for metastatic urothelial carcinoma. The patient developed asymptomatic episodes of recurring and remitting bilateral central serous chorioretinopathy correlating to erdafitinib dose modifications and interruptions. It is crucial for eye care providers to recognize the potential ocular adverse events related to erdafitinib, its drug class, and medications which target similar pathways.  Effective communication and careful co-management with oncology is essential in providing quality care to this subset of patients. With the care coordination, an effective yet tolerable dosing may provide the patient with increased survival rate and improved quality of life.

Downloads

Published

2022-11-23

How to Cite

Blanchard, S., Li, S., & Weiler, D. (2022). Erdafitinib-associated Central Serous Chorioretinopathy: A Case Report. Canadian Journal of Optometry, 84(4), 35–40. Retrieved from https://openjournals.uwaterloo.ca/index.php/cjo/article/view/4349